Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

NCT04255433 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04255433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04255433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
May 29, 2020
Completion date
June 12, 2025
Enrollment
13,299 (actual)
Sites
635

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus